No Data
Xiamen Amoytop Biotech's Q1 Profit Climbs 41%, Operating Income Rises 23%; Shares Drop 8%
Tebao Biotech: Tebao Biotech: Report for the first quarter of 2025
Tebao Biotech: Report for the first quarter of 2025
Xiamen Amoytop Biotech (688278.SH): In the first quarter, the net income is 0.182 billion yuan, a year-on-year increase of 41.40%.
Gelonghui, April 22 - Xiamen Amoytop Biotech (688278.SH) announced its first quarter report for 2025, achieving revenue of 0.673 billion yuan, a year-on-year increase of 23.48%; net income attributable to shareholders of the listed company of 0.182 billion yuan, a year-on-year increase of 41.40%; basic EPS of 0.45 yuan.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Is Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Trading At A 47% Discount?
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
